Agency Collection Notice for Older Americans Act Recipients Study
The Administration on Aging (AoA) has submitted a proposed collection of information for the Older Americans Act Recipients study to the Office of Management and Budget (OMB) for review. The study aims to collect data on service usage and satisfaction from recipients of various AoA-funded programs.
State Long-Term Care Ombudsman Programs Correction
The Administration on Aging (AOA) has published a correction to a final rule concerning State Long-Term Care Ombudsman programs. This document addresses minor technical and typographical errors identified in the original rule published on February 11, 2015. The corrections are effective December 19, 2016.
Proposed Rule for State Long-Term Care Ombudsman Program
The Administration on Aging (AoA) has issued a proposed rule to implement provisions of the Older Americans Act for the State Long-Term Care Ombudsman program. This rulemaking provides the first regulatory guidance for these programs, aiming to clarify implementation and reduce state-level variations. Comments are due by August 19, 2013.
DEA Designates Propionyl Chloride as List I Chemical
The DEA has finalized a rule designating propionyl chloride as a List I chemical under the Controlled Substances Act. This action subjects handlers of propionyl chloride to regulatory provisions due to its use in the illicit manufacture of fentanyl and its analogues. The rule becomes effective on April 9, 2026.
DEA Notice: Stepan Company Application for Bulk Controlled Substance Manufacturer
The DEA has published a notice regarding Stepan Company's application to be registered as a bulk manufacturer of cocaine and ecgonine. Interested parties can submit comments or requests for a hearing by May 12, 2026.
DEA Notice: Lonza Tampa LLC Application for Controlled Substance Importer Registration
The DEA has published a notice regarding an application from Lonza Tampa, LLC to be registered as an importer of psilocybin (Schedule I controlled substance). Interested parties can submit comments or requests for a hearing by April 13, 2026.
DEA Notice: Patheon API Services Controlled Substance Application
The DEA has published a notice regarding an application from Patheon API Services Inc. to be registered as a bulk manufacturer of controlled substances, including Dimethyltryptamine, Psilocybin, Psilocyn, Amphetamine, and Methadone. Interested parties can submit comments or requests for a hearing by May 12, 2026.
ACA Benefit Parameters and Basic Health Program Correction Proposed Rule
The Department of Health and Human Services (HHS) is issuing a correction to a proposed rule concerning the Affordable Care Act (ACA) benefit parameters and the Basic Health Program. This correction addresses technical errors, specifically the omission of column headings in several tables within the original proposed rule published on February 11, 2026.
NIH Amends Clinical Trials Registration and Results Submission Rule
The National Institutes of Health (NIH) has issued a final rule making a technical amendment to its clinical trials registration and results submission regulation. This amendment updates the URL for accessing information on formatting and submission procedures from the old prsinfo.clinicaltrials.gov to the new clinicaltrials.gov website. The change is effective December 9, 2024.
NIH Terminates Minority Biomedical Research Support Program
The Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), is repealing the regulation for the Minority Biomedical Research Support (MBRS) program. This action is effective September 25, 2025, and aligns with recent Supreme Court decisions and executive orders concerning discrimination and DEI programs.
NIH Delays Effective Date for Privacy Act Exemptions
The National Institutes of Health (NIH) has further delayed the effective date for a final rule concerning Privacy Act exemptions for its police records. The effective date is now May 5, 2025, extended from the previously scheduled March 21, 2025.
NIH Delays Effective Date for Privacy Act Rule
The National Institutes of Health (NIH) has delayed the effective date of a final rule concerning a new Privacy Act system of records. The rule, originally set to take effect on February 18, 2025, is now delayed until March 21, 2025, in accordance with a presidential memorandum.
NIH Privacy Act Implementation Final Rule
The National Institutes of Health (NIH) has published a final rule implementing exemptions for a new Privacy Act system of records, 'NIH Police Records.' This rule exempts certain law enforcement investigatory materials from specific Privacy Act requirements to protect ongoing investigations and sources.
Uniformed Services University Board of Regents Meeting Notice
The Uniformed Services University of the Health Sciences (USUHS) has issued a notice for its Board of Regents quarterly meeting. The meeting will cover the approval of minutes, departmental reports, and degree conferrals, essential for maintaining accreditation and fulfilling the university's mission.
Proposed Rule to Remove Opioid Disorder Treatment Waiver Requirements
SAMHSA has issued a supplemental notice of proposed rulemaking to remove the waiver requirement for practitioners prescribing certain medications for opioid use disorder (OUD). This action follows amendments made by the Consolidated Appropriations Act, 2023, which eliminated the need for the waiver. Public comments are due by March 14, 2023.
SAMHSA Seeks Public Comments on Maternal Mental Health
The Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting public comments on questions related to maternal mental health. This consultation aims to gather input for the Task Force on Maternal Mental Health.
Proposed Rule: Opioid Use Disorder Medication Regulations
The Department of Health and Human Services (HHS) has issued a Notice of Proposed Rulemaking to solicit public comment on proposed modifications to regulations concerning medications for opioid use disorder treatment. The comment period closes on February 14, 2023.
Proposed Federal Workplace Drug Testing Guidelines
The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a proposed rule to update federal workplace drug testing guidelines. This consultation seeks public comment on the proposed changes to these guidelines.
SAMHSA Proposed Rule: Mandatory Drug Testing Guidelines Using Oral Fluid
The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a proposed rule to establish mandatory guidelines for drug testing using oral fluid. This proposal aims to provide a standardized framework for federal agencies and contractors conducting such testing.
HHS Proposes Rescinding LGBTQI+ Children Placement Rule
The Administration for Children and Families (ACF) proposes to remove a final rule concerning designated placement requirements for LGBTQI+ children in foster care. This action follows a court decision vacating the rule, which the court found exceeded HHS's statutory authority. The public comment period for this proposed rescission ends April 6, 2026.
HHS Drug Testing Panel Guidelines
The Department of Health and Human Services (HHS) has issued updated guidelines for authorized drug testing panels used in federal workplace drug testing programs. The current drug testing panels for urine and oral fluid, along with the required nomenclature for laboratory and Medical Review Officer Reports, remain in effect as of July 7, 2025, with minor edits to footnotes for clarity.
HHS Opioid Use Disorder Medications Correction
The Department of Health and Human Services (HHS) is issuing a correcting amendment to the final rule on Medications for the Treatment of Opioid Use Disorder. This document corrects outdated references within the regulation, with an effective date of February 23, 2026.
HHS Modifies Privacy Act System of Records
The Department of Health and Human Services (HHS) is modifying a Privacy Act system of records, System No. 09-90-0052, to include reporting on substance use disorder patient records. The comment period for these modifications ends on March 19, 2026.
FDA Acknowledgment Letter to Special FX Rentals
The FDA's Center for Devices and Radiological Health (CDRH) has issued an acknowledgment letter to Special FX Rentals. This notice confirms receipt of documentation and does not indicate approval or disapproval of any submissions.
FDA Acknowledgment Letter to North Bay Productions
The FDA's Division of Management and Budget (DMB) issued an acknowledgment letter to North Bay Productions on March 13, 2026. This notice confirms receipt of a submission from the company.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2191-0001. This document is open for public comment, with a deadline for submissions.
FDA Complaint Document Details
The US Food and Drug Administration (FDA) has posted details regarding a complaint document. The document is available for review, though no specific details about its content or the nature of the complaint are provided in the notice.
FDA Complaint Document
The FDA has posted a complaint document related to enforcement actions. The document, authored by CTP, is available for review. Further details on the specific allegations and parties involved are not provided in the initial posting.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2392-0001. The document is available for download, though no specific details about the complaint's nature or the involved parties are provided in the metadata.
Osteopathic Family Physician Background Material
The FDA has posted background material related to Osteopathic Family Physicians. This notice provides informational content for stakeholders in the healthcare field.
FDA Natural Family Planning Review
The FDA has posted a review concerning Natural Family Planning methods. This document provides updated information and guidance related to these methods.
FDA Document on Ovarian Cancer Risk Factors
The FDA has released a document concerning risk factors associated with ovarian cancer. This guidance is intended for manufacturers and healthcare providers involved in the pharmaceutical and medical device sectors.
Draft Labeling for Atomoxetine HCL Solution
The FDA has posted draft labeling for Atomoxetine HCL Solution for public comment. This document outlines proposed changes to the drug's labeling, which will impact manufacturers and potentially healthcare providers.
Strattera Oral Solution SMPC Posting
The FDA has posted the Summary of Product Characteristics (SMPC) for Strattera oral solution on March 13, 2026. This posting provides updated information regarding the drug's characteristics and usage. It is intended for informational purposes for drug manufacturers and healthcare professionals.
FDA Proposes Pediatric Labeling Changes for ADHD Drugs
The FDA has issued a proposal to update the pediatric labeling for certain Attention Deficit Hyperactivity Disorder (ADHD) drugs. This consultation seeks public comment on the proposed changes to ensure accurate and up-to-date information for healthcare providers and patients regarding the use of these medications in children.
FDA Acknowledgment Letter to Irish Multimedia, LLC
The FDA has issued an acknowledgment letter to Irish Multimedia, LLC regarding a submission. The letter confirms receipt of the submission but provides no substantive details on its content or purpose.
FDA Complaint - Public Comment Period Closed
The FDA has posted a complaint document related to FDA-2026-H-2396-0001. The public comment period for this complaint has now closed. No specific details about the complaint's content or the agency's next steps are available in the provided information.
FDA Document Details
The Food and Drug Administration (FDA) has published details for a new document on regulations.gov. This notice provides access to the document and its associated information for interested parties. Further details regarding the document's content are available via the provided URL.
FDA Natural Family Planning Curricula Background Material
The FDA has posted background material related to Natural Family Planning curricula. This notice provides informational resources for interested parties.
FDA Complaint for Public Comment
The FDA has posted a complaint for public comment, with the comment period closing on March 13, 2026. The complaint was authored by the CTP and is available for download.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2387-0001. The document is authored by CTP and is available for download. This indicates a new enforcement action or investigation has been initiated.
FDA Document - Copyrighted Content
The FDA has posted a document containing copyrighted content, identified by the docket number FDA-2026-P-2640-0004. The content itself is restricted due to copyright. This notice serves to inform the public of the document's availability and its restricted nature.
FDA Variance Approval Letter
The FDA has issued a variance approval letter to Richard Lathrop, authored by CDRH. The letter, which contains restricted personally identifiable information, has been redacted and is available for download.
FDA Approves Labeling for RS, ANDA 202682
The U.S. Food and Drug Administration (FDA) has approved labeling for RS, as indicated by ANDA 202682. This approval was posted on March 13, 2026, and pertains to specific drug product labeling.
FDA Acknowledgment Letter to Athyna Pharma
The FDA's Center for Drug Evaluation and Research (CDER) has issued an acknowledgment letter to Athyna Pharma, LLC. This notice confirms receipt of a submission from the company.
FDA Approves Labeling for RLD, NDA N021411
The FDA has approved labeling for RLD (Reference Listed Drug) and NDA (New Drug Application) N021411. This notice indicates a regulatory action related to drug approval and labeling requirements.